1355052-34-4

Upstream product

• 1765-93-1 4-fluoroboronic acid 
• 55102-99-3 1-bromo-4-(4-fluorophenoxy) benzene 
• 73183-34-3 bis(pinacol)diborane 
• 106-41-2 4-bromo-phenol 
• 2561-25-3 4-(4-fluorophenoxy)-1-nitrobenzene 
• 36160-82-4 4-(4-fluorophenoxy)aniline 
• 886762-45-4 1-fluoro-4-(4-iodophenoxy)benzene 
• 350-46-9 4-Fluoronitrobenzene 
• 371-41-5 4-Fluorophenol 
• 269409-70-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 

Downstream Products

• 1355052-35-5 methyl 6-(4-(4-fluorophenoxy)phenyl)picolinate 
• 1355052-62-8 methyl 4-chloro-6-(4-(4-fluorophenoxy)phenyl)picolinate 
• 1355052-41-3 C₂₀H₁₆FNO₃ 
• 361436-85-3 6-(4-(4-fluorophenoxy)phenyl)picolinic acid 
• 1599467-74-9 6-chloro-4-ethoxy-3-(4-(4-fluorophenoxy)phenyl)-7-methoxy-2-methylquinoline 
• 1354745-77-9 6-chloro-3-(4-(4-fluorophenoxy)phenyl)-7-methoxy-2-methylquinolin-4(1H)-one 
• 1426336-49-3 6-(N-(2,3-dihydroxypropyl)methylsulfonamido)-2-(4-(4-fluorophenoxy)phenyl)pyrimidine-4-carboxamide 
• 1383709-76-9 (S)-methyl 2-((4-chloro-6-(4-(4-fluorophenoxy)phenyl)pyridin-2-yl)amino)propanoate 
• 1383709-74-7 N-(6-(4-(4-(trifluoromethyl)phenoxy)phenyl)pyridin-2-yl)acrylamide 
• 1383709-70-3 C₂HF₃O₂*C₂₂H₂₂FN₃O 
• 1383709-68-9 C₂₇H₃₀FN₃O₃ 
• 1383708-77-7 N-(6-(4-(4-fluorophenoxy)phenyl)pyridin-2-yl)methanesulfonamide 
• 1383708-75-5 (S)-N-(4-(1,2-dihydroxyethyl)-6-(4-(4-fluorophenoxy)phenyl)pyridin-2-yl)methanesulfonamide 
• 1383709-60-1 (S)-4-(2,2-dimethyl-1,3-dioxolan-4-yl)-6-(4-(4-fluorophenoxy)phenyl)pyridin-2-amine 

Relevant academic research and scientific papers

DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

Discovery, synthesis, and optimization of antimalarial 4(1 H)-quinolone-3-diarylethers

The historical antimalarial compound endochin served as a structural lead for optimization. Endochin-like quinolones (ELQ) were prepared by a novel chemical route and assessed for in vitro activity against multidrug resistant strains of Plasmodium falciparum and against malaria infections in mice. Here we describe the pathway to discovery of a potent class of orally active antimalarial 4(1H)-quinolone-3-diarylethers. The initial prototype, ELQ-233, exhibited low nanomolar IC50 values against all tested strains including clinical isolates harboring resistance to atovaquone. ELQ-271 represented the next critical step in the iterative optimization process, as it was stable to metabolism and highly effective in vivo. Continued analoging revealed that the substitution pattern on the benzenoid ring of the quinolone core significantly influenced reactivity with the host enzyme. This finding led to the rational design of highly selective ELQs with outstanding oral efficacy against murine malaria that is superior to established antimalarials chloroquine and atovaquone.

SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASES INHIBITORS

The present invention is directed to novel pyrazolopyrimidines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities against BTK and/or EGFR T790M and are useful for the treatment of protein kinases mediated diseases and conditions.

HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS

The invention relates to aryl substituted compounds of Formula (I) : and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein Het, G, A, R, and n are defined as set forth in the specification. The invention is also directed to the use

PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS

The invention relates to substituted pyridine compounds of Formula I: (I) or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein A1, X, A2, R1a, R1b, R1c, G, and z are defined as

PYRIDINE COMPOUNDS AND THE USES THEREOF

The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.